Intelligence Profile
Science
SGLT2 inhibitors, or sodium-glucose cotransporter-2 inhibitors, are a class of medications primarily used to manage type 2 diabetes by influencing glucose reabsorption in the kidneys. These drugs target the SGLT2 proteins located in the proximal renal tubules. Under normal conditions, these proteins reabsorb approximately 90% of the glucose filtered by the kidneys back into the bloodstream. By inhibiting SGLT2, these medications reduce glucose reabsorption, leading to increased glucose excretion through urine and a reduction in blood glucose levels.
Beyond their glucose-lowering effects, SGLT2 inhibitors have shown benefits in cardiovascular and renal outcomes. A study examining their long-term use in patients with heart failure with preserved ejection fraction (HFpEF) indicated improvements in myocardial strain and diastolic function, which are linked to reduced myocardial fibrosis (Frontiers in Cardiovascular Medicine, 2026). This suggests potential benefits in cardiac function likely due to favorable hemodynamic changes and reduced cardiac workload.
Additionally, SGLT2 inhibitors can induce an initial dip in estimated glomerular filtration rate (eGFR) upon initiation, especially in chronic kidney disease patients, although this might stabilize over time (Clinical and Experimental Nephrology, 2026). These changes can protect kidney function in the long term by decreasing intraglomerular pressure.
The broader effects of SGLT2 inhibitors, such as potential reductions in cardiovascular mortality and protection against heart failure, highlight their diverse roles beyond glucose control, suggesting an impact on underlying disease mechanisms.
Disclaimer: This information is for educational purposes and not intended as medical advice. Always consult a healthcare professional for medical decisions.